Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Maj 2026

Biotek-snakken — Maj 2026

Planlagt Fastgjort Låst Flyttet Biotek-snakken
26 Indlæg 1 Posters 233 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #11

    Lidt mere om konkurrencen:

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #12

      Regnskab Arvinas 12 maj

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #13

        Link Preview Image
        Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

        NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be ava

        favicon

        Yahoo Finance (finance.yahoo.com)

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote sidst redigeret af
          #14

          Zymeworks nede 11% - må vist hellere få hørt CC fra i går. Det er godt nok vilde tider for biotek.

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote sidst redigeret af
            #15

            Man orker det snart ikke mere…..

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote sidst redigeret af
              #16

              1111% er jo ingenting 😉

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote sidst redigeret af
                #17

                Og det skulle være 11% 🙂

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote sidst redigeret af
                  #18

                  Biotech i europa ligner snart US mht kursudsving

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote sidst redigeret af
                    #19

                    Link Preview Image
                    Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

                    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer), subject to regulatory clearance, to develop, manufacture and commercialize VEPPANU™ (vepdegestrant), the first and only U.S. Food and Drug Administration (FDA)-approved oral PROteolysis TArgeting Chimera (PROTAC). PROTACs are part of a

                    favicon

                    Yahoo Finance (finance.yahoo.com)

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote sidst redigeret af
                      #20

                      Så fik Pfizer og Arvinas en partner til deres nyligt godkendte degrader

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote sidst redigeret af
                        #21

                        Sukkeralf, der var da ikke noget i deres CC som skulle kunne få den ned med 10+%. udsættelse af IND til næste år med en god forklaring tror jeg ikke var årsagen.Tænker der er komme lidt flere retail investorer i den pga af de fine stigninger som solgte ud pga det på papiret dårlige regnskab. bum bum

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote sidst redigeret af
                          #22

                          Næh jeg synes heller ikke det helt giver mening, men synes mange af mine biotek investeringer er lidt svage pt.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote sidst redigeret af
                            #23

                            Synes de nævnte at der ville komme prispres i Europa på zanidatamab, så måske det påvirker peaksale forventningerne.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote sidst redigeret af
                              #24

                              Der kommer snart interim analyse af OS i GEA, så den skal helst ikke være svag frem mod dette.

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                LP90
                                wrote sidst redigeret af
                                #25

                                Godmorgen 🙂

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  LP90
                                  wrote sidst redigeret af
                                  #26

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lahn1
                                    wrote sidst redigeret af
                                    #27

                                    Nææ, den må godt lige svknge op tol $27-$30 op til data

                                    1 Reply Last reply
                                    0

                                    Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                    Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                    With your input, this post could be even better 💗

                                    Tilmeld Log ind
                                    Svar
                                    • Svar som emne
                                    Login for at svare
                                    • Ældste til nyeste
                                    • Nyeste til ældste
                                    • Most Votes


                                    • Log ind

                                    • Har du ikke en konto? Tilmeld

                                    • Login or register to search.
                                    Powered by NodeBB Contributors
                                    • First post
                                      Last post
                                    0
                                    • Kategorier
                                    • Seneste
                                    • Etiketter
                                    • Populære
                                    • Verden
                                    • Bruger
                                    • Grupper